- Cancer Biology & Biomarkers
- Chromatography & Mass Spectrometry
- Contract Research, Clinical Trials and Outsourcing
- Drug Discovery
- Drug Targets
- Flow Cytometry
- Informatics & Lab Automation
- Ingredients, Excipients and Dosages
- Microbiology & RMMs
- NIR, PAT & QbD
- Raman Spectroscopy
- Screening, Assays & High-Content Analysis
- Thermal Processing
- Events & Workshops
BMS and PsiOxus to evaluate Opdivo and enadenotucirev in cancer
1 July 2016 • Author: Victoria White, Digital Content Producer
Bristol-Myers Squibb and PsiOxus are to evaluate the safety, tolerability, and preliminary efficacy of PsiOxus’ enadenotucirev in combination with Bristol-Myers Squibb’s Opdivo (nivolumab) to treat a range of tumour types in late-stage cancer patients.
PsiOxus’ enadenotucirev is an oncolytic group B adenovirus therapeutic that is given intravenously. Enadenotucirev is a virus that selectively replicates in tumour cells but not in normal cells. Such viruses promote anti-tumour responses through a dual mechanism of action that is dependent on selective tumour cell killing and the induction of systemic anti-tumour immunity. Preclinical data demonstrate that this approach is potentially applicable to a broad range of epithelially derived solid tumours, many of which have compelling unmet needs even when treated with checkpoint inhibitors.
Opdivo is a PD-1 immune checkpoint inhibitor that binds to the checkpoint receptor PD-1 expressed on activated T-cells, and blocks the binding of PD-L1 and PD-L2, preventing the PD-1 pathway’s suppressive signalling on the immune system, including the interference with an anti-tumour immune response.
Collaboration will support Phase I studies
The clinical collaboration between PsiOxus and Bristol-Myers Squibb will support Phase I studies to determine whether combining these two agents can significantly improve the proportion of patients achieving objective tumour responses, the extent of tumour shrinkage, and/or the durability of responses.
Commenting on the collaboration, Jean Viallet, M.D., Global Clinical Research Lead, Oncology, Bristol-Myers Squibb, said: “This collaboration continues to expand our clinical development of Opdivo and explores how oncolytic viruses may provide a complementary mechanism to address tumours that are resistant to I-O therapy. We are excited to partner with PsiOxus to evaluate the combination of Opdivo and enadenotucirev to accelerate our understanding of its potential as a new therapeutic option for cancer patients.”
John Beadle, M.D., Chief Executive Officer, PsiOxus, commented on working with Bristol-Myers Squibb: “They are our ideal partner since we share a common vision of exploring novel combinations such as enadenotucirev and Opdivo to expand the range of patients who potentially respond favourably to checkpoint inhibitor therapy.”
ABB Analytical Measurement ACD/Labs ADInstruments Ltd Advanced Analytical Technologies GmbH Analytik Jena AG Astell Scientific Ltd B&W Tek Bachem AG Bibby Scientific Limited Bio-Rad Laboratories BioNavis Ltd Biopharma Group Black Swan Analysis Limited Charles Ischi AG | Kraemer Elektronik Cherwell Laboratories CI Precision Cobalt Light Systems Coulter Partners CPC Biotech srl Dassault Systèmes BIOVIA DiscoverX Edinburgh Instruments Enterprise System Partners (ESP) EUROGENTEC F.P.S. Food and Pharma Systems Srl IDBS JEOL Europe L.B. Bohle Maschinen + Verfahren GmbH Lab M Ltd. LabWare Linkam Scientific Instruments Limited Metrohm Molins Technologies Multicore Dynamics Ltd Nanosurf New England Biolabs, Inc. Panasonic Biomedical Sales Europe B.V. PerkinElmer Inc ReAgent Russell Finex Limited Source BioScience Takara Clontech Tornado Spectral Systems Tuttnauer Watson-Marlow Fluid Technology Group Wickham Laboratories Limited Xylem Analytics YMC Europe GmbH Yusen Logistics